Amivantamab binds EGFR on target cells and engages Fcγ receptor–bearing effector cells (e.g., NK cells, macrophages) to induce ADCC/ADCP, leading to killing of EGFR+ cells; it also blocks signaling and promotes receptor internalization/degradation.